Touchlight is revolutionising DNA and has developed a way to manufacture synthetic DNA vectors, called dbDNA™ (or “doggybone” DNA)
By moving away from restrictive biological approaches, Touchlight’s unique dbDNA™ vector is optimised for use in advanced genetic medicines, being safer and more efficacious than conventional plasmid DNA. The platform, based on enzymatic technology, enables DNA production at unprecedented scale, speed and purity.
Touchlight is leveraging its platform to develop the next generation of DNA vaccines for oncology and infectious diseases, in-house and in collaboration with industry partners and academics, as well as enabling manufacture of advanced therapies (viral vectors, mRNA vaccines, and cell therapies) through their CDMO, Touchlight DNA Services.
Novator invested in 2021.